相似文献
1
Lysosome-targeted octadecyl-rhodamine B-liposomes enhance lysosomal accumulation of glucocerebrosidase in Gaucher's cells in vitro.
Nanomedicine (Lond). 2013 Jul;8(7):1055-65. doi: 10.2217/nnm.12.138. Epub 2012 Dec 2.
2
Screening and optimization of ligand conjugates for lysosomal targeting.
Bioconjug Chem. 2011 Nov 16;22(11):2271-82. doi: 10.1021/bc200336j. Epub 2011 Oct 6.
3
Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B.
J Drug Target. 2011 Sep;19(8):606-14. doi: 10.3109/1061186X.2010.550921. Epub 2011 Jan 29.
4
Ultrastructural localization of glucocerebrosidase in cultured Gaucher's disease fibroblasts by immunocytochemistry.
J Neurol. 1987 Jan;234(1):44-51. doi: 10.1007/BF00314009.
5
Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
Mov Disord. 2016 Nov;31(11):1610-1618. doi: 10.1002/mds.26802. Epub 2016 Sep 13.
6
Comparison of rates of hydrolysis of N-oleoyl and N-stearoyl glucocerebroside in patients with Gaucher's disease.
Biochim Biophys Acta. 1979 Oct 26;575(1):27-36. doi: 10.1016/0005-2760(79)90127-9.
7
Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease.
Int J Biochem Cell Biol. 2005 Nov;37(11):2310-20. doi: 10.1016/j.biocel.2005.05.008.
8
Incorporation of glucocerebrosidase into Gaucher's disease monocytes in vitro.
Proc Natl Acad Sci U S A. 1979 Jan;76(1):473-5. doi: 10.1073/pnas.76.1.473.
9
Gaucher's disease in the presence of normal glucocerebrosidase activity.
Hum Pathol. 1992 May;23(5):588-92. doi: 10.1016/0046-8177(92)90139-t.
10
Enzymic differentiation of neurologic and nonneurologic forms of Gaucher's disease.
J Neuropathol Exp Neurol. 1982 Nov;41(6):630-41. doi: 10.1097/00005072-198211000-00006.
引用本文的文献
1
Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders.
Adv Drug Deliv Rev. 2023 Jun;197:114683. doi: 10.1016/j.addr.2022.114683. Epub 2023 Jan 16.
2
Novel Approaches of Dysregulating Lysosome Functions in Cancer Cells by Specific Drugs and Its Nanoformulations: A Smart Approach of Modern Therapeutics.
Int J Nanomedicine. 2021 Jul 26;16:5065-5098. doi: 10.2147/IJN.S321343. eCollection 2021.
3
CNS-Targeting Therapies for Lysosomal Storage Diseases: Current Advances and Challenges.
Front Mol Biosci. 2020 Nov 12;7:559804. doi: 10.3389/fmolb.2020.559804. eCollection 2020.
4
Reduced glucocerebrosidase activity in monocytes from patients with Parkinson's disease.
Sci Rep. 2018 Oct 18;8(1):15446. doi: 10.1038/s41598-018-33921-x.
5
Reversible glycosidic switch for secure delivery of molecular nanocargos.
Nat Commun. 2018 May 10;9(1):1843. doi: 10.1038/s41467-018-04225-5.
6
Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.
Adv Drug Deliv Rev. 2017 Sep 1;118:109-134. doi: 10.1016/j.addr.2017.05.004. Epub 2017 May 11.
7
Drug delivery in overcoming the blood-brain barrier: role of nasal mucosal grafting.
Drug Des Devel Ther. 2017 Jan 27;11:325-335. doi: 10.2147/DDDT.S100075. eCollection 2017.
8
Lysosomal Re-acidification Prevents Lysosphingolipid-Induced Lysosomal Impairment and Cellular Toxicity.
PLoS Biol. 2016 Dec 15;14(12):e1002583. doi: 10.1371/journal.pbio.1002583. eCollection 2016 Dec.
9
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery.
Nat Rev Drug Discov. 2014 Nov;13(11):813-27. doi: 10.1038/nrd4333. Epub 2014 Oct 7.
10
Nanopreparations for organelle-specific delivery in cancer.
Adv Drug Deliv Rev. 2014 Feb;66:26-41. doi: 10.1016/j.addr.2013.11.004. Epub 2013 Nov 21.
本文引用的文献
1
Enzyme replacement therapy for lysosomal storage diseases.
Curr Opin Pediatr. 2011 Dec;23(6):588-93. doi: 10.1097/MOP.0b013e32834c20d9.
2
Screening and optimization of ligand conjugates for lysosomal targeting.
Bioconjug Chem. 2011 Nov 16;22(11):2271-82. doi: 10.1021/bc200336j. Epub 2011 Oct 6.
3
Bone marrow-targeted liposomal carriers.
Expert Opin Drug Deliv. 2011 Mar;8(3):317-28. doi: 10.1517/17425247.2011.553218. Epub 2011 Jan 31.
4
Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B.
J Drug Target. 2011 Sep;19(8):606-14. doi: 10.3109/1061186X.2010.550921. Epub 2011 Jan 29.
5
Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.
Blood Cells Mol Dis. 2011 Jan 15;46(1):119-23. doi: 10.1016/j.bcmd.2010.07.008. Epub 2010 Aug 19.
6
Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment.
J Inherit Metab Dis. 2010 Jun;33(3):271-9. doi: 10.1007/s10545-010-9071-0. Epub 2010 Mar 25.
7
The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages.
PLoS One. 2010 Jan 13;5(1):e8668. doi: 10.1371/journal.pone.0008668.
8
Phenotype, diagnosis, and treatment of Gaucher's disease.
Lancet. 2008 Oct 4;372(9645):1263-71. doi: 10.1016/S0140-6736(08)61522-6.
9
Fabry's disease.
Lancet. 2008 Oct 18;372(9647):1427-35. doi: 10.1016/S0140-6736(08)61589-5.
10
Pompe's disease.
Lancet. 2008 Oct 11;372(9646):1342-53. doi: 10.1016/S0140-6736(08)61555-X.
Zotero 插件